PracticeUpdate: Haematology & Oncology
VOL. 2 • NO. 2 • 2017
RESEARCH NEWS AND VIEWS FROM ELSEVIER
Identifying key molecular alterations in prostate cancer
... in the triplet combination, cetuximab likely serves to counteract feedback-loop activation of EGFR after BRAF blockade. It will remain to be seen if regulatory agencies, guideline committees will see the results as practice-changing 19 EDITOR’S PICKS Longer-interval dosing of zoledronic acid effective in patients with bone metastases 7 8 Small renal mass biopsy avoids unnecessary surgery mpMRI for diagnosing prostate cancer recurrence superior to PET, CT ECCO 2017
It is imperative to unravel prostate cancer biology to enable the identification of key molecular events and molecules that aid in diagnosis, prognosis, and the discovery of new therapeutic targets. 3
Simultaneous EGFR, BRAF inhibition effective in BRAF V600-mutated mCRC
More patients with rectal cancer are candidates for a watch-and- wait approach
Improved survival benefit with increased docetaxel cycles in prostate cancer JAMA Oncology The study results indicate that continuing docetaxel chemotherapy improves clinical benefit in patients with mCPRC, but further prospective studies are needed to validate these findings.
First-line ceritinib vs platinum-based chemotherapy in advanced ALK- rearranged non-small cell lung cancer The Lancet Ceritinib was associated with a significant improvement compared with chemotherapy as a first-line treatment in patients with ALK- rearranged NSCLC.
Vemurafenib in metastatic melanoma patients with brain metastases Annals of Oncology The results showed that melanoma BM responded in a clinically meaningful way to vemurafenib. This agent can be administered without causing significant CNS toxicity.
Made with FlippingBook